Zymeworks (NASDAQ:ZYME – Free Report) had its price objective lifted by HC Wainwright from $51.00 to $55.00 in a research report released on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Zymeworks’ Q3 2026 earnings at $2.14 EPS, Q4 2026 earnings at $0.67 EPS, FY2026 earnings at $1.51 EPS, Q1 2027 earnings at $1.05 EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at $0.76 EPS, Q4 2027 earnings at ($0.34) EPS and FY2027 earnings at $1.32 EPS.
ZYME has been the topic of a number of other research reports. Citigroup reaffirmed a “market outperform” rating on shares of Zymeworks in a report on Wednesday. Stifel Nicolaus set a $46.00 price target on Zymeworks in a report on Friday, August 7th. B. Riley Financial reiterated a “buy” rating and set a $44.00 price objective (up from $40.00) on shares of Zymeworks in a research report on Monday, August 10th. Deutsche Bank Aktiengesellschaft set a $32.00 price objective on Zymeworks in a report on Wednesday. Finally, Truist Financial lifted their target price on Zymeworks from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.00.
Check Out Our Latest Analysis on Zymeworks
Zymeworks Trading Down 2.6%
Zymeworks (NASDAQ:ZYME – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.06). The company had revenue of $3.23 million during the quarter, compared to analyst estimates of $4.54 million. Zymeworks had a negative return on equity of 72.30% and a negative net margin of 405.31%.Zymeworks’s quarterly revenue was down 90.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.03 earnings per share. As a group, equities analysts forecast that Zymeworks will post 1.37 earnings per share for the current fiscal year.
Zymeworks announced that its board has approved a share repurchase program on Thursday, May 14th that authorizes the company to buyback $125.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 7% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its shares are undervalued.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Deutsche Bank AG bought a new stake in Zymeworks during the second quarter worth approximately $10,383,000. Kornitzer Capital Management Inc. KS acquired a new stake in shares of Zymeworks in the fourth quarter valued at $2,338,000. Rubric Capital Management LP boosted its stake in Zymeworks by 21.7% during the first quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock valued at $175,280,000 after buying an additional 1,250,000 shares in the last quarter. Bank of America Corp DE boosted its stake in Zymeworks by 164.5% during the first quarter. Bank of America Corp DE now owns 236,754 shares of the company’s stock valued at $5,928,000 after buying an additional 147,230 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Zymeworks by 8.1% during the fourth quarter. Vanguard Group Inc. now owns 2,328,727 shares of the company’s stock worth $61,315,000 after acquiring an additional 174,293 shares during the period. 92.89% of the stock is currently owned by institutional investors.
Key Stories Impacting Zymeworks
Here are the key news stories impacting Zymeworks this week:
- Positive Sentiment: The U.S. Food and Drug Administration approved Ziihera (zanidatamab-hrii), both with and without tislelizumab plus chemotherapy, for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma. The expanded approval broadens Zymeworks’ commercial opportunity and could improve the long-term revenue outlook for its lead product. FDA approves Ziihera for first-line HER2-positive advanced gastroesophageal cancer
- Positive Sentiment: HC Wainwright maintained a Buy rating and a $55 price target while sharply raising its earnings outlook. Its FY2026 EPS estimate increased to $1.51 from $0.31, and its FY2027 estimate moved to $1.32 from a prior loss estimate of $1.72 per share. The firm also raised several quarterly forecasts, signaling greater confidence in Ziihera-related earnings potential. HC Wainwright raises Zymeworks earnings estimates
- Positive Sentiment: Citigroup reportedly forecast substantial price appreciation, while Citizens JMP assigned Zymeworks a market outperform rating. These calls add further analyst support following the FDA decision. Citigroup forecasts strong price appreciation for Zymeworks Citizens JMP rates Zymeworks market outperform
- Neutral Sentiment: The immediate catalyst is primarily regulatory and expectations-driven; investors will likely look for prescription growth, launch execution and evidence that the approval translates into sustainable revenue and earnings.
About Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.
At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.
Featured Stories
- Five stocks we like better than Zymeworks
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
